Insider Transactions in Q3 2024 at Bio Xcel Therapeutics, Inc. (BTAI)
Insider Transaction List (Q3 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 17
2024
|
Frank Yocca Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
21,250
+37.48%
|
-
|
|
Sep 17
2024
|
Javier Rodriguez Officer |
BUY
Grant, award, or other acquisition
|
Direct |
21,250
+40.96%
|
-
|
|
Sep 17
2024
|
Matthew T. Wiley Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
21,250
+45.67%
|
-
|
|
Sep 17
2024
|
Vincent O'Neill Officer |
BUY
Grant, award, or other acquisition
|
Direct |
21,250
+45.79%
|
-
|
|
Sep 17
2024
|
Richard I Steinhart Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
21,250
+43.63%
|
-
|
|
Sep 16
2024
|
Javier Rodriguez Officer |
SELL
Open market or private sale
|
Direct |
345
-3.64%
|
$0
$0.69 P/Share
|
|
Sep 16
2024
|
Richard I Steinhart Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
356
-5.43%
|
$0
$0.69 P/Share
|
|
Sep 16
2024
|
Vimal Mehta CEO and President |
SELL
Open market or private sale
|
Direct |
1,982
-1.86%
|
$0
$0.69 P/Share
|
|
Sep 16
2024
|
Frank Yocca Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
355
-2.44%
|
$0
$0.69 P/Share
|
|
Sep 16
2024
|
Matthew T. Wiley Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
215
-5.06%
|
$0
$0.69 P/Share
|
|
Sep 16
2024
|
Vincent O'Neill Officer |
SELL
Open market or private sale
|
Direct |
138
-3.41%
|
$0
$0.69 P/Share
|
|
Sep 15
2024
|
Javier Rodriguez Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
563
+5.61%
|
-
|
|
Sep 15
2024
|
Richard I Steinhart Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
563
+7.9%
|
-
|
|
Sep 15
2024
|
Vimal Mehta CEO and President |
BUY
Exercise of conversion of derivative security
|
Direct |
3,500
+6.12%
|
-
|
|
Sep 15
2024
|
Frank Yocca Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
563
+3.72%
|
-
|
|
Sep 15
2024
|
Matthew T. Wiley Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
750
+15.01%
|
-
|
|
Sep 14
2024
|
Javier Rodriguez Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
521
+5.52%
|
-
|
|
Sep 14
2024
|
Richard I Steinhart Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
521
+7.99%
|
-
|
|
Sep 14
2024
|
Vimal Mehta CEO and President |
BUY
Exercise of conversion of derivative security
|
Direct |
2,609
+4.95%
|
-
|
|
Sep 14
2024
|
Frank Yocca Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
521
+3.59%
|
-
|
|
Sep 14
2024
|
Vincent O'Neill Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
521
+11.41%
|
-
|